Abstract
Abstract The present report concerns HPLC method development for chemical samples of a new antiarrhythmic drug 2-methyl-5-phenyl-5-[2-[2-N, N-bis (1-methylethyl amino] ethyl]-1,3 diazabicyclo [4.4.0] octen-4-one (MPMED). Selectivity optimization for MPMED and several synthetic process intermediates with reversed-phase HPLC conditions is described. Also, the use of electrochemical and UV absorption detection for MPMED samples has been evaluated. The developed method has been validated for generation of assay data for chemical lots of MPMED.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
